Ownership history in Frazier Life Sciences Management, L.P. · 15 quarters on record
This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in VAXCYTE INC (PCVX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 474,405 | — | 0% | 0.51% | $17.1M | $36.02 |
| 2025 Q2 | REDUCED | 474,405 | -65,000 | -12.1% | 0.62% | $15.4M | $32.51 |
| 2025 Q1 | UNCHANGED | 539,405 | — | 0% | 0.93% | $20.4M | $37.76 |
| 2024 Q4 | REDUCED | 539,405 | -340,000 | -38.7% | 1.83% | $44.2M | $81.86 |
| 2024 Q3 | REDUCED | 879,405 | -160,000 | -15.4% | 4.03% | $100.5M | $114.27 |
| 2024 Q2 | REDUCED | 1,039,405 | -100,000 | -8.8% | 3.67% | $78.5M | $75.51 |
| 2024 Q1 | REDUCED | 1,139,405 | -25,000 | -2.1% | 3.28% | $77.8M | $68.31 |
| 2023 Q4 | UNCHANGED | 1,164,405 | — | 0% | 3.91% | $73.1M | $62.80 |
| 2023 Q3 | UNCHANGED | 1,164,405 | — | 0% | 3.94% | $59.4M | $50.98 |
| 2023 Q2 | REDUCED | 1,164,405 | -233,000 | -16.7% | 3.47% | $58.2M | $49.94 |
As of 2025 Q4 — sorted by position size